On September 21, 2026, at its Capital Markets Day investor briefing, Novo Nordisk reported topline results from two Phase 3 trials of CagriSema — the fixed-dose combination of the amylin analogue cagrilintide and semaglutide. In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg produced 12.4% weight loss at week 60 versus 9.1% for tirzepatide 5 mg, meeting superiority on weight and non-inferiority on HbA1c. In REDEFINE 9, the same 1.0 mg/1.0 mg dose produced 21.0% weight loss at week 68 versus 2.0% for placebo in adults with overweight or obesity.
Two things make this readout worth reading closely rather than from the headline. The first is that this is the first head-to-head in which CagriSema has beaten tirzepatide on weight — and the comparator dose moved down to get there. The second, and the more consequential number for dose-efficiency questions in the amylin class, is that REDEFINE 9's low-dose result lands within roughly two percentage points of what the full 2.4 mg/2.4 mg dose produced in an earlier trial.
Research-context information only. Cagrilintide and semaglutide are discussed here as research compounds and, in semaglutide's case, as an approved pharmaceutical. CagriSema is an investigational combination not approved by the FDA. Trial figures reported below come from company announcements and published trial results. Research-peptide forms of semaglutide and tirzepatide are not FDA-approved and are sold for research purposes only. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What Novo reported
REIMAGINE 5 was a 68-week Phase 3 trial in approximately 1,000 adults with type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor, or both, with dual primary endpoints assessed at week 60.
| Endpoint (REIMAGINE 5) | CagriSema 1.0/1.0 mg | Tirzepatide 5 mg | Result |
|---|---|---|---|
| Weight loss, week 60 | 12.4% | 9.1% | Superiority met |
| HbA1c reduction, week 60 | 1.71 points | 1.67 points | Non-inferiority met |
REDEFINE 9 ran 68 weeks in adults with overweight or obesity, testing two CagriSema doses — 1.0 mg/1.0 mg and 1.7 mg/1.7 mg — against placebo, as an adjunct to reduced-calorie diet and increased physical activity.
| Endpoint (REDEFINE 9) | CagriSema 1.0/1.0 mg | Placebo |
|---|---|---|
| Weight loss, week 68 | 21.0% | 2.0% |
Novo also reported improvements in systolic blood pressure, waist-to-height ratio and fasting lipid profile in REDEFINE 9. Topline figures for the 1.7 mg/1.7 mg arm were not broken out in the announcement. In both trials the company described CagriSema as well tolerated overall, with a safety profile consistent with previous studies; per-arm adverse event and discontinuation rates were not disclosed at topline.
Martin Holst Lange, Novo's EVP of Research and Development and Chief Scientific Officer, framed the result as "superior weight loss versus tirzepatide 5 mg as well as strong results across obesity and type 2 diabetes."
The comparator dose is the story
CagriSema has now been run against tirzepatide three times, and the pattern only makes sense when the doses are laid side by side.
| Trial | Reported | Population | CagriSema dose | Tirzepatide dose | Weight outcome |
|---|---|---|---|---|---|
| REDEFINE 4 | Feb 2026 | Obesity, 809 adults, 84 wks | 2.4/2.4 mg | 15 mg | 23.0% vs 25.5% — non-inferiority missed |
| REIMAGINE 4 | Aug 2026 | Type 2 diabetes, ~1,000 adults, 68 wks | 2.4/2.4 mg | 15 mg | 15.2% — non-inferiority met on weight, missed on HbA1c |
| REIMAGINE 5 | Sep 2026 | Type 2 diabetes, ~1,000 adults, 68 wks | 1.0/1.0 mg | 5 mg | 12.4% vs 9.1% — superiority met |
Against tirzepatide 15 mg, the highest approved dose, CagriSema's full 2.4/2.4 mg formulation could not clear the bar on weight in obesity. Against tirzepatide 5 mg — the lowest maintenance dose in a ladder that runs to 15 mg — a CagriSema dose well below its own studied maximum did.
That is not necessarily an unfair design. Per tirzepatide labeling and the CagriSema trial protocols, each comparator is a low-to-mid dose on its own titration ladder, and gastrointestinal adverse events are commonly cited in the incretin literature as a reason people do not escalate past the lower maintenance doses. A trial that compares what people actually stay on is a legitimate question to ask, and arguably a more useful one than a maximum-dose contest.
It is also a related dose-matching issue to the one Novo itself raised in court. In July 2026 the company asked a court to halt Lilly's GLP-1 advertising for pitting maximum-dose tirzepatide against outdated semaglutide doses. Two months later, Novo's own superiority headline rests on a comparator running at a third of its approved ceiling. Both things can be defensible trial design and awkward positioning at the same time. The practical takeaway across this coverage is the same in either direction: when a GLP-1 headline says one compound beat another, the doses are the first thing to check.
The dose-efficiency number
REDEFINE 9 is the readout with the most direct bearing on the research channel, and it has been under-covered because "beats tirzepatide" is the better headline.
In REDEFINE 1, reported in 2025 and published in the New England Journal of Medicine, CagriSema 2.4 mg/2.4 mg produced 22.7% weight loss at week 68 versus 2.3% for placebo. REDEFINE 9 now reports 21.0% at week 68 at 1.0 mg/1.0 mg — a dose carrying roughly 42% as much total material.
| Trial | CagriSema dose | Weight loss, week 68 | Placebo |
|---|---|---|---|
| REDEFINE 1 | 2.4/2.4 mg | 22.7% | 2.3% |
| REDEFINE 9 | 1.0/1.0 mg | 21.0% | 2.0% |
This is a cross-trial comparison, not a controlled head-to-head. REDEFINE 1 and REDEFINE 9 enrolled separate populations at separate times with separate baseline characteristics, and the two figures were not generated under a single randomisation. Novo has not published a dose-response curve linking them. A within-trial answer will come from the 1.7 mg/1.7 mg arm of REDEFINE 9 when its figures are released, since that arm sits between the two doses in the same population.
With that caveat carrying real weight, the shape of the result is still worth noting — as a cross-trial reading, not a conclusion Novo has drawn: most of the effect appears to arrive early on the titration ladder, and the last 1.4 mg of each component appears to add a comparatively small increment of additional weight loss. That is a familiar pattern across the incretin class — semaglutide 7.2 mg produced 20.7% against 17.5% for the 2.4 mg dose in STEP UP, a 3.2-point gain for triple the material — but REDEFINE 9 puts a sharper number on it for the amylin combination specifically.
What the low-dose data means for research-channel pricing
Disclosure: The Peptide Catalog earns a commission on some vendor links on this page, and bacteriostatic water is sold by a business the site's owner operates. Prices on linked pages are the vendors' listed prices.
Cagrilintide and semaglutide trade separately in the research channel, priced per milligram. CagriSema, the fixed-dose combination, is not something a vendor sells — it is an investigational product filed with the FDA, with a decision expected in Q4 2026. What changes today is information, not access.
The low-dose figure is the part most relevant to how these compounds are priced. Novo's trials tested a supervised fixed-dose combination product; they did not test separately sourced research material, and nothing in the readout establishes that the 21.0% result carries over to it. What the readout adds is a second reference point — both 1.0 mg/1.0 mg and 2.4 mg/2.4 mg per component now have a published 68-week figure attached to them, where before only the higher one did. Reported protocol ranges for cagrilintide are covered in our cagrilintide dosing guide, and the cagrilintide evidence base separate from the combination is in cagrilintide benefits.
Per-milligram cost is where a dose finding lands. The two trial doses differ 2.4-fold in material per component, and this article does not suggest any dose for research material. Live per-milligram pricing across every vendor we list is on the best cagrilintide vendors and best semaglutide vendors pages, and current discount codes are consolidated on our deals page. Prices and coupons move weekly, so the live figure is the one that matters rather than any number written into an article.
Nothing in this readout changes tirzepatide's position. REIMAGINE 5 compared a low tirzepatide dose. The 15 mg head-to-heads still stand as reported, and in the obesity trial at maximum doses tirzepatide produced the larger weight reduction. A dose comparison is not a compound comparison. Our semaglutide vs tirzepatide breakdown and the tirzepatide buying guide cover the trial-by-trial picture.
Tolerability, not efficacy, is what the low-dose finding speaks to. Lower doses are studied in part because gastrointestinal adverse events are a commonly reported driver of discontinuation across this class. Novo did not disclose per-arm adverse event rates at topline, so the tolerability comparison between the 1.0/1.0 and 2.4/2.4 doses is not yet answerable from published data. Reported adverse events for the individual compounds are documented in tirzepatide side effects for the comparator arm.
